Weight Loss Injections for Men: UK Guide

Weight loss injections for men are increasingly prescribed in the UK as part of a structured approach to managing obesity and related health conditions. Medicines such as semaglutide (Wegovy) and tirzepatide (Mounjaro) work by mimicking gut hormones to reduce appetite and regulate blood sugar, offering a clinically supported option alongside diet and exercise. This article explains how these injections work, which products are MHRA-authorised, what they cost, and who qualifies for treatment on the NHS or privately, helping men make informed decisions about their weight management options.

How do weight loss injections actually work in the body?

Weight loss injections mimic gut hormones (GLP-1, and GIP for tirzepatide) to reduce appetite, slow gastric emptying and signal fullness to the brain, supporting reduced calorie intake alongside diet and exercise.

Weight loss injections work by mimicking gut hormones that regulate appetite, blood sugar and the rate at which the stomach empties, leading to reduced calorie intake and, over time, meaningful weight loss. The medicines currently used in the UK belong to a class called GLP-1 receptor agonists, or to a newer dual-action class that targets both GLP-1 and GIP receptors. These hormones are naturally released after eating and signal to the brain that the body is full.

In practical terms, men using these medicines typically experience a significant reduction in hunger and food cravings. The stomach empties more slowly, which prolongs the feeling of fullness after meals. Clinical trial data also suggest improvements in metabolic markers such as blood glucose, blood pressure and cholesterol in people living with obesity, though the magnitude of these effects varies between individuals and between medicines.

The dual GLP-1 and GIP receptor agonist tirzepatide (Mounjaro) activates two complementary hormonal pathways simultaneously. The SURMOUNT-5 head-to-head trial compared tirzepatide 10 mg or 15 mg against semaglutide 2.4 mg in adults with obesity or overweight and found greater average weight reduction with tirzepatide at those doses; results should be interpreted in the context of the doses studied and the trial population. Semaglutide (Wegovy) acts on the GLP-1 receptor alone and has a well-established evidence base across multiple large trials, including the STEP programme.^[4][9] Both are administered as weekly subcutaneous injections. Patients should follow the injection site guidance in the Patient Information Leaflet and Instructions for Use supplied with their specific device, which typically lists the abdomen, thigh or upper arm as suitable sites.

It is important to understand that these medicines are intended to support a reduced-calorie diet and increased physical activity, not to replace them. They are not stimulants or fat-burning agents in the traditional sense; their primary mechanism is hormonal appetite regulation.

Which weight loss injections are available to men in the UK?

Three MHRA-authorised injectable weight management medicines are available in the UK: semaglutide (Wegovy), tirzepatide (Mounjaro) and liraglutide (Saxenda), all administered subcutaneously and suitable for eligible men.

Three injectable medicines are currently authorised by the MHRA for chronic weight management in adults in the UK: semaglutide 2.4 mg (Wegovy, also available in a 7.2 mg strength), tirzepatide (Mounjaro) and liraglutide 3 mg (Saxenda). All are subcutaneous injections and are suitable for men who meet the relevant clinical criteria.

Wegovy contains semaglutide, a GLP-1 receptor agonist. It is supplied as a dial-a-dose pen containing four weekly doses and is started at a low dose that is gradually increased over several months to the maintenance level. The MHRA has also authorised a higher 7.2 mg strength, extending the dose range beyond the previously available 2.4 mg ceiling. A separate semaglutide product, Ozempic, is MHRA-authorised for type 2 diabetes management rather than weight management, and should not be used interchangeably with Wegovy for this purpose.^[20][15]

Mounjaro contains tirzepatide and is MHRA-authorised both for type 2 diabetes and for chronic weight management.^[16][17] It is supplied as a multiple-dose KwikPen, with each pen containing four weekly doses. The dose is escalated gradually from 2.5 mg weekly up to a maximum of 15 mg weekly, depending on tolerability and clinical response.

Saxenda contains liraglutide and is an older GLP-1 receptor agonist that is administered daily rather than weekly. It remains MHRA-authorised for weight management, though it is less commonly initiated now that weekly options exist.

Men considering treatment should have a thorough clinical assessment to determine which medicine, if any, is appropriate for their individual circumstances. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where Mounjaro or Wegovy may be considered if clinically appropriate.

How much do weight loss injections cost per month in the UK?

Private monthly costs vary by medicine, dose and provider; NHS patients in England pay the standard prescription charge per item, though access depends on local ICB commissioning decisions.

The private monthly cost of weight loss injections in the UK varies depending on the medicine, the dose strength and the provider, and men should be aware that consultation fees are separate from medication costs. Private prices for these medicines are set by individual pharmacies and clinics and are not regulated in the same way as NHS charges.

For indicative reference, the BNF publishes list prices for these medicines; one Mounjaro KwikPen contains four weekly doses and represents one month of treatment. Private retail prices may differ from BNF list figures, and men should check current prices directly with their provider. Wegovy pricing similarly varies by dose strength and supplier. Men should always confirm whether a quoted price includes the prescriber consultation, any follow-up support and delivery, or whether these are charged separately.

On the NHS, men who are prescribed a weight management medicine pay the standard prescription charge per item if they are in England and do not hold an exemption certificate. A prescription prepayment certificate (PPC) can reduce costs significantly for those who require multiple items; current PPC charges are published by the NHS Business Services Authority (NHSBSA) at nhsbsa.nhs.uk and are updated periodically. Prescription charges do not apply in Wales, Scotland or Northern Ireland.

It is worth noting that NHS access to these medicines is subject to local commissioning decisions by Integrated Care Boards (ICBs), and availability varies across England.^[9][11] NICE technology appraisals for both Wegovy and Mounjaro recommend their use as part of a specialist weight-management service rather than as a standalone prescription.^[9][11] Men who do not qualify for NHS-funded treatment, or who face long waiting times, often explore private routes. Comparing providers on the basis of clinical governance, prescriber qualifications and aftercare support is as important as comparing price.

Who qualifies for weight loss injections on the NHS or privately?

NHS eligibility is generally guided by NICE criteria, typically a BMI of 35 kg/m² or above plus at least one weight-related comorbidity; private providers follow similar clinical principles with individual assessment.

Eligibility for weight loss injections, whether on the NHS or through a private provider, is determined by a combination of body mass index (BMI), the presence of weight-related health conditions, and an individual clinical assessment. NICE technology appraisals set out the criteria that NHS commissioners use as a starting point, though local ICBs make the final commissioning decisions and criteria can differ between areas.

For NHS access, NICE guidance on semaglutide (Wegovy) specifies a BMI of 35 kg/m² or above alongside at least one weight-related comorbidity, such as type 2 diabetes, hypertension, obstructive sleep apnoea or cardiovascular disease, as a general threshold.^[9][10] Men with a BMI between 30 and 34.9 kg/m² may also be considered in certain circumstances, including those from ethnic groups at higher metabolic risk at lower BMI thresholds. NICE guidance on tirzepatide (Mounjaro) sets out comparable criteria. Treatment is recommended as part of a specialist weight-management service rather than as a standalone prescription.

For private access, eligibility criteria broadly follow the same clinical principles, though individual providers may apply slightly different thresholds. A responsible private provider will conduct a thorough medical history review, assess suitability and confirm that the chosen medicine is appropriate before prescribing.

Men should also be aware of important safety considerations. The only contraindication listed in the UK SmPCs for both Wegovy and Mounjaro is hypersensitivity to the active substance or any excipient.^[23][24] Separately, the UK SmPCs include warnings and precautions that a prescriber will consider: acute pancreatitis has been reported in post-marketing data, including cases with serious outcomes, and any severe or persistent abdominal pain should prompt contact with a GP or, if symptoms are severe and sudden, attendance at A&E.^[2] The SmPCs also include precautions relating to a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, gallbladder disease, and, in people with type 2 diabetes, pre-existing diabetic retinopathy.^[23][24] These are matters for the prescribing clinician to assess individually. Suspected side effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions